SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on speculation that SELLASs Phase 3 REGAL AML trial is nearing its final event trigger and subsequent topline analysis, with traders reacting to CEO commentary and favorable remarks from pharmaceutical-industry professionals. The community remains sharply divided: bulls view the prolonged survival and outside commentary as supportive, while bears question the trial design, delayed event timing, and likelihood of a successful readout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Preliminary second-quarter results showing sharply improved operating profitability despite lower revenue, together with an amended convertible-note exchange that limits stock issuance and shifts the remainder to cash, are driving attention. Traders are divided between viewing the developments as evidence of improving fundamentals and reduced dilution risk, and focusing on revenue declines, management concerns, and unusual warrant activity that has fueled speculative squeeze discussion.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Celina, Texass reported conversion of its city WiFi into Helium-powered carrier coverage is driving attention, with traders viewing the deployment and broader carrier-offload use case as evidence of real-world DePIN adoption. Bullish commenters expect continued momentum, while skeptics question token dilution, hotspot profitability, and whether network usage will translate into value for HNT holders.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Anticipation of broader federal marijuana rescheduling to Schedule III, including an upcoming administrative-law recommendation, is driving attention as traders expect reduced tax burdens and improved institutional access for U.S. cannabis operators. The community remains largely bullish on Trulieves positioning and NYSE listing, while others warn that the catalyst is not yet finalized and cite profit-taking, overbought conditions, and post-earnings concerns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Strong Phase 3 data for CAN-2409 in localized prostate cancer, along with anticipation of ASTRO findings and a planned Q4 BLA submission, is driving bullish attention. Traders see potential regulatory and pharmaceutical-partnership upside, while skeptics point to dilution risk, the unfiled BLA, profit-taking, and broader biotech momentumincluding enthusiasm around cancer-vaccine developmentsas competing factors.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Positive Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia, including substantial triglyceride reductions and fewer acute pancreatitis events, are driving attention and expectations for a broader regulatory filing. Traders are broadly bullish on REDEMPLOs commercial potential and Arrowheads RNAi platform, although some debate the valuation, competition from Ionis, and the stocks volatile sell-the-news trading.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Reports of renewed U.S.-Iran hostilities, tanker attacks, and severely disrupted Strait of Hormuz flows are driving attention to USO, with traders debating whether the supply shock will lift crude prices. The Venezuela oil agreement and possible diplomatic reopening are viewed by bears as longer-term supply relief, while bulls argue infrastructure limits mean they will not quickly offset the disruption.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Upcoming quarterly earnings are the dominant catalyst, with traders focused on whether Broadcoms AI custom-chip and networking demand will support stronger guidance. Bulls expect a beat and continued momentum from OpenAI and hyperscaler projects, while bears argue expectations are already elevated and remain concerned about debt, potential Google-related share loss, and another post-earnings selloff.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Canadian government funding for Xanadus quantum-manufacturing Project OPTIMISM is driving attention, while traders debate whether additional federal and Ontario support will materialize. The community is split between viewing the backing as validation of Xanadus photonic technology and warning that heavy cash burn, limited revenue, and potential dilution could offset the benefit.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Ongoing buyout speculation is the dominant topic, with traders pointing to Vandas approved products, NEREUSs potential as a GLP-1 nausea treatment, and the broader pharmaceutical M&A environment. The community remains divided, as optimism about the pipeline and perceived undervaluation competes with concerns over management, heavy spending, cash burn, and possible dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omada Health (OMDA) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Is Hinge Health Stock a Buy as Growth Accelerates and Risks Rise?

HNGE's rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.

Hinge Health's Cylinder Deal Opens a $135B GI Care Growth Opportunity

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

HNGE Rallies 64.6% in 3 Months as Growth and Margins Gain Momentum

Hinge Health 64.6% three-month rally is backed by surging revenues, wider margins and a raised 2026 outlook, but execution expectations are rising.

Omada Health, Inc. (OMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Omada Health, Inc. (OMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Omada Health, Inc. (OMDA) Q2 Earnings and Revenues Top Estimates

Omada Health, Inc. (OMDA) delivered earnings and revenue surprises of +200.00% and +8.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Omada Health Reaches Analyst Target Price

In recent trading, shares of Omada Health Inc (Symbol: OMDA) have crossed above the average analyst 12-month target price of $23.33, changing hands for $23.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on val...

Omada Health, Inc. (OMDA) Is Up 7.18% in One Week: What You Should Know 

Does Omada Health, Inc. (OMDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Omada Health CEO Sean Duffy Sells 17,000 Shares. What Does This Mean for Investors?

Key PointsSean P. Duffy sold 17,258 shares for $342,000 across three days ending June 26...

Omada Health, Inc. (OMDA) Stock Jumps 10.5%: Will It Continue to Soar?

Omada Health, Inc. (OMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

• Reported GAAP EPS of $0.09 up 137.50% YoY
• Reported revenue of $87.83M up 43.12% YoY
• For the year ending December 31, 2026, Omada Health expects revenue in the range of $334 million to $340 million and adjusted EBITDA in the range of $21 million to $27 million.

Omada Health faces material risks including customer and channel partner concentration, dependence on third-party suppliers, potential seasonality impacts, and the ongoing challenge of maintaining profitability in a competitive healthcare market.

Omada Health demonstrated strong growth with a 45% increase in total members and record gross margins, while expanding its market reach through new partnerships and the launch of cholesterol management services.

Omada Health, Inc. engages in the provision of digital health services. It offers online diabetes and obesity prevention programs, health coaching, and integration of web, mobile, and smart devices. The company was founded by Andrew DiMichele, Adrian James, and Sean Duffy in 2011 and is headquartered in South San Francisco, CA.

Omada Health Inc.

Omada Health Stock Jumps Into Retail Focus As Wall Street Lifts Price Targets After ‘Beat And Raise’ Quarter, GLP-1 Push

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$23.69
Prev Close	$24.27
Open	$24.32
Dividend Yield	0.00%
50-Day Moving Average	$22.18
Beta	0.95
Avg. Volume	1.27M
PE Ratio	360.03

52-Week High	$26.92
52-Week Low	$10.28
Market Capitalization	$1.45B
EPS (Annual)	-$0.2187
Price to Book	5.68
Revenue Per Employee	$284,072.05

Feed

News

Sentiment

Earnings

Fundamentals

Info